



Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference

May 11, 2017

Live Audio Webcast Will be on May 17, 2017

SAN DIEGO, May 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas.

The live presentation takes place on Wednesday, May 17 at 8:40am PT (11:40am ET). The presentation will be webcast and may be accessed on the Company's website at <http://www.neurocrine.com>.

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. In April of 2017, the FDA approved INGREZZA® (valbenazine) capsules for the treatment of adults with Tardive Dyskinesia (TD). INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first and only FDA-approved product indicated for the treatment of adults with TD. The Company markets INGREZZA in the United States. The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA (valbenazine), a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette Syndrome.

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at <http://www.neurocrine.com>.

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-bank-of-america-merrill-lynch-2017-healthcare-conference-300456289.html>

SOURCE Neurocrine Biosciences, Inc.

Investor Relations, ir@neurocrine.com